BioSpace News Archive

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced a publication in Nature led by researchers from Memorial Sloan Kettering Cancer Center that could broaden the potential benefits for KRAS G12C inhibitors like sotorasib in patients with lung cancer and other solid tumors.

InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, announced the publication of the first comprehensive analysis providing significant support for the existence of naturally pluripotent stem cells in all organs.

Merck today announced that Health Canada has granted conditional approval for KEYTRUDA.

ViewRay, Inc. today announced the closing of an additional 1,875,000 shares of common stock following the exercise in full of the underwriters’ option to purchase additional shares in connection with its recently completed public offering of 12,500,000 shares of common stock.

4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in a fireside chat at the Evercore ISI HealthCONx 2021 Conference.

Amyris, Inc. (Nasdaq: AMRS) (“Amyris”), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market™ operating platform, today announced that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the first subjects have been enrolled in the MIRA-3 Phase 3 pivotal trial evaluating Nyxol® Eye Drops in the reversal of pharmacologically-induced mydriasis (dilation of the pupil).

Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Piper Sandler 33rd Annual Healthcare Conference on Tuesday, November 30, 2021 at 2:00 p.m. Eastern Time.

Donaldson Company, Inc., a leading worldwide provider of innovative filtration products and solutions, announced it acquired Solaris Biotechnology Srl.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in Evercore ISI’s 4th Annual HealthCONx Virtual Conference.